Envista (NYSE:NVST) Reaches New 12-Month High Following Analyst Upgrade

Shares of Envista Holdings Corporation (NYSE:NVST) hit a new 52-week high on Thursday after Barclays raised their price target on the stock from $24.00 to $34.00. Barclays currently has an overweight rating on the stock. Envista traded as high as $30.42 and last traded at $30.1890, with a volume of 3500017 shares trading hands. The stock had previously closed at $30.17.

Several other equities research analysts also recently weighed in on NVST. Wall Street Zen raised Envista from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 26th. Evercore restated an “outperform” rating and issued a $32.00 target price on shares of Envista in a research note on Friday, February 6th. Mizuho boosted their price target on Envista from $24.00 to $27.00 and gave the company a “neutral” rating in a report on Tuesday. Leerink Partners set a $35.00 price objective on Envista and gave the stock an “outperform” rating in a research report on Friday, February 6th. Finally, Evercore ISI set a $32.00 target price on shares of Envista and gave the company an “outperform” rating in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.43.

Insider Buying and Selling

In other Envista news, SVP Mischa Reis sold 9,675 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total transaction of $290,250.00. Following the transaction, the senior vice president owned 32,382 shares of the company’s stock, valued at approximately $971,460. The trade was a 23.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.66% of the company’s stock.

More Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Barclays raised its price target from $24 to $34 and moved NVST to an “overweight” rating, signaling stronger institutional conviction and giving the stock more upside momentum. Article Title
• Positive Sentiment: Short interest dropped ~23.3% in January to ~8.09M shares (about 5.0% of float, 3.1 days to cover), reducing one bearish force and removing a potential short-squeeze overhang. (Data reported 2/10/2026)
• Positive Sentiment: Zacks and other broker commentary have highlighted NVST as a buy/upgrade candidate amid sector rotation and AI-related market noise, reinforcing the positive analyst narrative around growth and execution. Article Title
• Positive Sentiment: Coverage highlighting Envista as a strong growth stock and noting that the name is gaining renewed focus as healthcare/NYSE composites strengthen, supporting continued investor interest. Article Title
• Neutral Sentiment: Mizuho raised its price target from $24 to $27 but kept a “neutral” rating — a modest improvement but still below the current market level, which may temper upside expectations for some investors. Article Title
• Negative Sentiment: Insider selling: SVP Mischa Reis sold 9,675 shares at about $30 (roughly $290K), reducing her stake by ~23%. Insider sales can create short-term nervousness about insider conviction even when not uncommon. SEC Filing

Institutional Investors Weigh In On Envista

A number of hedge funds have recently modified their holdings of NVST. Holocene Advisors LP purchased a new position in Envista during the second quarter worth about $43,936,000. Norges Bank acquired a new stake in shares of Envista during the 4th quarter worth approximately $45,113,000. Alliancebernstein L.P. raised its position in shares of Envista by 34.0% during the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after buying an additional 1,547,656 shares during the period. Franklin Resources Inc. lifted its holdings in Envista by 16.7% in the second quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock valued at $175,011,000 after acquiring an additional 1,284,767 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Envista in the third quarter valued at approximately $24,260,000.

Envista Stock Up 0.1%

The firm has a 50-day moving average of $23.36 and a two-hundred day moving average of $21.43. The company has a quick ratio of 2.04, a current ratio of 2.38 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $4.96 billion, a PE ratio of 107.82, a price-to-earnings-growth ratio of 2.06 and a beta of 1.01.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.32 by $0.06. The business had revenue of $750.60 million for the quarter, compared to analyst estimates of $680.26 million. Envista had a return on equity of 6.54% and a net margin of 1.73%.The company’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities research analysts predict that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.